IL4 and atopic eczema: Another common driver of itch, IL-13 [53], was elevated for IV, EI, and TTD patients (P2 and P3), suggesting that the atopic dermatitis biologics tralokinumab or lebrikizumab, both IL-13 inhibitors, might prove useful in reducing itch and inflammation in some CI patients [54], or alternatively, the IL-4/IL-13 inhibitor dupilumab.